Pfizer, Serum File EUAs For COVID-19 Vaccines In India

Questions Remain Over Serum's Adverse Event

07 Dec 2020

Pfizer and separately Serum Institute, which is partnering Oxford/AstraZeneca's COVID-19 candidate, have filed for emergency use authorizations of their vaccines in India. While Pfizer is yet to conduct clinical trials in India, questions over a serious adverse event during Serum's trials linger despite the regulator's clean chit.

As COVID-19 Vaccines Zip Ahead To Launch, Questions Linger • Source: Shutterstock

Pfizer Ltd. (India) and Serum Institute of India Pvt. Ltd. filed for emergency use authorizations of their COVID-19 vaccines in India over the 5-6 December weekend. While the Pfizer Inc./BioNTech SE mRNA candidate recently became the first vaccine to be approved in the UK, it hasn't been in clinical trials in India and it remains to be seen if the US firm's Indian subsidiary will be directed to conduct limited local trials before approval.

Though Pfizer’s vaccine, which has to be stored at -70 Centigrade, is not a natural fit for India’s hot and humid climactic conditions, the company has suggested storage solutions to the government that could

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor Into Phase III For IPF

12 May 2025

• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.